Dasiglucagon (Zegalogue®)
Congenital hyperinsulinism (CHI) / Severe hypoglycemia
ApprovedMarketed/Partnership
Key Facts
Indication
Congenital hyperinsulinism (CHI) / Severe hypoglycemia
Phase
Approved
Status
Marketed/Partnership
Company
About Zealand Pharma
Zealand Pharma leverages its proprietary peptide platform to design and develop novel therapeutics, with a core focus on metabolic and gastrointestinal disorders. The company has achieved significant milestones, including the commercialization of V-Go® for diabetes and the advancement of a high-potential pipeline led by survodutide, a GLP-1/glucagon dual agonist with blockbuster potential in obesity. Strategic partnerships with Boehringer Ingelheim and a strong financial position underpin its strategy to become a leader in peptide therapeutics.
View full company profile